You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 23, 2024

Investigational Drug Information for Adavosertib

✉ Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Adavosertib?

Adavosertib is an investigational drug.

There have been 29 clinical trials for Adavosertib. The most recent clinical trial was a Phase 1 trial, which was initiated on January 30th 2015.

The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Adenocarcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), AstraZeneca, and Parexel.

Recent Clinical Trials for Adavosertib
Adavosertib and Gemcitabine in Advanced PancreaticAstraZenecaPhase 2
Adavosertib and Gemcitabine in Advanced PancreaticLustgarten FoundationPhase 2
Adavosertib and Gemcitabine in Advanced PancreaticStand Up To CancerPhase 2

See all Adavosertib clinical trials

Clinical Trial Summary for Adavosertib

Top disease conditions for Adavosertib
Top clinical trial sponsors for Adavosertib

See all Adavosertib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.